Wang Jiping, Sun Yihong, Bertagnolli Monica M
Division of Surgical Oncology, Brigham and Women's Hospital, Boston, MA, USA,
Ann Surg Oncol. 2015 Sep;22(9):2965-71. doi: 10.1245/s10434-015-4388-4. Epub 2015 Jan 29.
The prognosis for gastric cancer is better for Asian than for Caucasian patients. The primary driver of this difference is unknown. This study determined whether the survival advantage of Asian ethnicity continued to hold after control was used for other well-known prognostic factors.
In this study, 12,773 patients who underwent gastrectomy for treatment of adenocarcinoma of the stomach were identified from the Surveillance, Epidemiology, and End Results cancer registry. Patients with cardia tumor were excluded from the study. The independent prognostic effect of ethnicity was evaluated by adjusting for other known factors.
The Asian patients tended to have a diagnosis at an earlier age (66.8 vs. 68.5 years), more lymph nodes examined (16 vs. 13), and more positive lymph nodes (5.1 vs. 4.8). Survival was better for the Asian patients than for the Caucasian patients, with a 12 % 5-year survival difference. Among the patients with IB, IIA, and IIB disease, the Asian patients had 37, 72, and 13 months longer median survival time than the corresponding Caucasian patients. The multivariate Cox model showed persistence of this result after adjustment for imbalances of age, gender, tumor grade, and number of examined and positive lymph nodes. The largest risk reduction was observed for the stage IA patients (31 %) and the smallest for the stage IIIC patients (9 %).
After excluding proximal gastric cancers, controlling for the imbalance of known prognostic factors, and decreasing in the influence of D2 lymphadenectomy, stage migration, and chemo/radiation therapy by including only patients treated in the United States, this study found that the survival advantage of Asian ethnicity continued to be present.
胃癌患者中,亚洲人的预后比白种人更好。造成这种差异的主要原因尚不清楚。本研究旨在确定在控制了其他已知的预后因素后,亚洲人种的生存优势是否依然存在。
本研究从监测、流行病学和最终结果癌症登记处识别出12773例因胃腺癌接受胃切除术的患者。贲门肿瘤患者被排除在研究之外。通过对其他已知因素进行调整,评估人种的独立预后效应。
亚洲患者的诊断年龄往往更早(66.8岁对68.5岁),检查的淋巴结更多(16个对13个),阳性淋巴结也更多(5.1个对4.8个)。亚洲患者的生存率高于白种人患者,5年生存率相差12%。在IB、IIA和IIB期疾病患者中,亚洲患者的中位生存时间比相应的白种人患者分别长37、72和13个月。多变量Cox模型显示,在调整了年龄、性别、肿瘤分级以及检查和阳性淋巴结数量的不平衡后,这一结果仍然存在。IA期患者的风险降低幅度最大(31%),IIIC期患者最小(9%)。
在排除近端胃癌、控制已知预后因素的不平衡,并通过仅纳入在美国接受治疗的患者来减少D2淋巴结清扫、分期迁移以及化疗/放疗的影响后,本研究发现亚洲人种的生存优势依然存在。